Velsera is the discovery, evidence generation, and clinical delivery platform for precision medicine. Our mission is to empower life science and clinical diagnostics organizations to make data-driven decisions that accelerate the development and delivery of targeted therapies-ensuring the right treatment reaches the right patient at the right time.
Formed in 2023 through the merger of Seven Bridges, PierianDx, and UgenTec, Velsera brings together world-class expertise in bioinformatics, clinical interpretation, and workflow automation.
With operations in North America, Europe, and Asia, we serve customers across the globe who are advancing translational research, diagnostic innovation, and precision care.
Velsera provides software and expert services across three core domains:
- Multimodal Data Harmonization & Analytics for Drug Discovery & Development: We help researchers integrate and analyze complex datasets-including genomics, clinical, and real-world evidence-to unlock novel insights, identify biomarkers, and improve trial design.
- IVD Development, Validation & Approval: Velsera’s platform supports assay developers with streamlined, compliant workflows to accelerate the path from concept to market for molecular diagnostics.
- Clinical NGS Interpretation, Reporting & Adoption: We enable clinical laboratories to deliver high-quality, scalable NGS testing with automated interpretation, customizable reporting, and seamless integration into existing lab systems.
Velsera’s integrated approach bridges the gap between research and clinical application, enabling a more connected, efficient, and impactful precision medicine ecosystem. By aligning data, technology, and expertise across the full continuum of care, we help organizations translate discovery into action.
In this eBook, we explore key areas where bioinformatics is transforming drug discovery, diagnostics, and clinical decision-making. You’ll learn how to ensure your data is fit for purpose, what it really takes to move beyond AI hype and deliver measurable impact, and how to design bioinformatics solutions that meet evolving regulatory standards. We’ll also highlight cutting-edge applications of AI in gene and cell therapy, including breakthroughs in zinc finger protein design and cell differentiation. Whether you’re advancing research or preparing for clinical adoption, these insights will help you navigate the next wave of innovation in precision medicine.
The post Beyond the Bioinformatics Hype: How to Build Scalable, AI-Driven Tools That Deliver in Precision Medicine appeared first on GEN – Genetic Engineering and Biotechnology News.
